Interpharm Holdings

IPAH

Medical - Pharmaceuticals · Healthcare

Price

$0.00

+0.00 (+0.00%)

Market Cap

$660

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Share count rising — dilution

+833.6% over 5y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 7.0M (2002) → 65.2M (2007)

Interpharm Holdings is a generic pharmaceutical company based in the United States. It manufactures and sells generic versions of brand-name prescription and over-the-counter drugs. Its main customers are drug wholesalers, retail pharmacy chains, and distributors who supply medications to patients.

The company earns money by selling generic drug products, competing primarily on price against other generic manufacturers. Interpharm has operated mainly in the U.S. market and is a relatively small player in the generic drug industry, which is dominated by larger companies like Teva and Mylan. The main risk the business faces is intense price competition in the generic drug market, which compresses margins — as reflected in its negative operating margin — making it difficult to generate consistent profits without scale or a differentiated product portfolio.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-6.8% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-216.1% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$19M/ year

↑ Rising (+78% vs prior year)

25.1% of revenue

In line with sector average (18%)

Investing heavily in future products and technology

Insider Activity

69.8%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~0 months

$72,000 cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Heavy R&D investment

Interpharm Holdings is putting 25% of revenue into R&D and that number is rising.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

14.8%

Thin — 14.8% gross margin

Operating Margin

-47.9%

Losing money on operations — -47.9%

ROCE

-19.4%

Weak — -19.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-5.1%

Shrinking sales (-5.1% YoY)

EPS YoY

N/A

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

-42.8%

Burning cash (-42.8%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

2.32

Heavy debt load (2.32)

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial